Hutchinson-Gilford Progeria Syndrome

Overview

Hutchinson-Gilford Progeria Syndrome (HGPS, or progeria) is an ultra-rare genetic condition in which children develop features of accelerated aging, including severe growth failure, loss of body fat and hair, skin and joint changes, skeletal problems, and rapidly progressive cardiovascular disease. In approximately 90% of people with classic HGPS, a new (not inherited) change in the LMNA gene, c.1824C>T, causes cells to produce progerin, an abnormal form of the structural protein lamin A. Progerin damages cell nuclei and particularly affects blood vessels; intelligence is usually normal. GeneReviews: HGPS

The major cause of death is heart attack or stroke from premature atherosclerosis. Without lonafarnib, reported average survival is about 14.5 years; with treatment it is approximately 18.7 years. The current standard of care combines specialist monitoring and supportive management of cardiovascular, bone, dental, nutritional, hearing, eye, and mobility complications with lonafarnib (Zokinvy), a farnesyltransferase inhibitor approved in the United States in November 2020 to reduce mortality risk in eligible patients. Lonafarnib is disease-modifying but does not correct the genetic mutation or cure HGPS. GeneReviews: HGPS FDA Zokinvy approval letter

Scope of Recent Research (2020–present)

Research since 2020 has been unusually active for an ultra-rare disease because most classic cases share one highly targetable DNA change. The leading curative question is whether a therapy can safely correct or silence the mutant LMNA sequence throughout the body—especially in the heart and arteries—early enough to prevent irreversible vascular injury. Base editing, which changes a single DNA letter without deliberately cutting both DNA strands, has produced the strongest curative proof-of-concept in mice; RNA-targeting drugs and small molecules that lower progerin or block its harmful interactions are advancing as potentially more near-term treatments. No curative therapy has yet been demonstrated in people. In vivo base editing rescues HGPS in mice Systematic ASO screening for HGPS

Major Breakthroughs and Emerging Therapies

The most important advance is adenine base editing of the causal LMNA mutation. In a 2021 study, researchers packaged a base editor and guide RNA into two adeno-associated virus 9 (AAV9) vectors and gave a single intravenous dose to newborn HGPS-model mice. The treatment corrected the disease-associated DNA letter in multiple organs, reduced abnormal RNA splicing and progerin, improved aortic pathology, and substantially extended median survival from 215 to 510 days. In patient-derived cells, the same approach corrected the mutation in roughly 90% of treated cells. This is compelling evidence that repairing the root cause can reverse major biological features of HGPS, but it remains preclinical. In vivo base editing rescues HGPS in mice NIH summary of base editing study

Follow-up work has made the vascular rationale for editing more concrete. In 2025, investigators used induced pluripotent stem cells—adult cells reprogrammed into a stem-cell-like state—to make engineered human blood vessels containing HGPS endothelial and smooth-muscle cells. Correcting LMNA with an adenine base editor restored nitric-oxide signaling, vessel constriction and relaxation, smooth-muscle-cell density, and markers of fibrosis toward healthy levels. Vessels containing at least half edited cells showed particularly substantial functional recovery, helping define how much editing may be needed in a future therapy. Base editing in engineered HGPS blood vessels

A second strategy is to reduce production of progerin at the RNA level. A 2021 systematic screen of 198 antisense oligonucleotides (ASOs)—short synthetic nucleic acids that alter or block RNA processing—identified lead compounds that suppress the faulty LMNA splice product and extended survival in HGPS mice. More recently, a 2025 study designed small interfering RNAs (siRNAs) that selectively lowered progerin in patient fibroblasts while preserving normal lamin A and lamin C; combining the siRNAs with lonafarnib produced an additive effect in cells. These approaches avoid permanent DNA alteration, but still require a safe way to repeatedly deliver RNA drugs to the cardiovascular system and other affected tissues. Systematic ASO screening for HGPS Selective siRNAs for HGPS

Small-molecule approaches remain important because they can be given orally and may complement mutation-targeting treatment. Progerinin (SLC-D011) is designed to disrupt binding between progerin and lamin A, thereby reducing a harmful protein interaction rather than changing DNA. It improved premature-senescence features in HGPS cells and improved cardiac and arterial measurements in an HGPS mouse model. Other experimental approaches aim to improve removal of progerin through autophagy, the cell’s recycling process, or to reduce downstream inflammation and cellular stress; however, these remain supportive or disease-modifying concepts rather than curative strategies. Progerinin in HGPS cells Progerinin improves cardiac abnormalities in mice Ghrelin in HGPS fibroblasts

Clinical Trials and Experimental Approaches

The most notable current interventional study is a Phase 2a trial of progerinin plus lonafarnib versus lonafarnib alone, sponsored by PRG Science & Technology Co., Ltd. The trial began on January 13, 2025, enrolled 10 participants at Boston Children’s Hospital, and was listed as active but not recruiting in its February 9, 2026 update. Its primary aims are to determine an appropriate dose and assess safety, tolerability, and pharmacokinetics; no efficacy results had been posted. NCT06775041: Progerinin plus lonafarnib

Boston Children’s Hospital also sponsors a Phase I/II study of everolimus plus lonafarnib. Everolimus inhibits mTOR, a cellular signaling pathway that regulates autophagy and metabolism. The study is assessing dose-limiting toxicities, the maximum tolerated dose, and potential efficacy; it was listed as enrolling by invitation in April 2026, with no posted results. Laboratory work in engineered HGPS blood vessels found that the combination improved several vascular measures more than lonafarnib alone, but this does not establish clinical benefit. Lonafarnib monotherapy continues as the approved standard treatment and as an extension option for affected individuals. NCT02579044: Everolimus plus lonafarnib Lonafarnib and everolimus in engineered vessels FDA Zokinvy prescribing information

Methodologies and Scientific Approaches

HGPS research combines patient-derived fibroblasts, genetically engineered mouse models, and increasingly sophisticated human vascular models. The latter include induced-pluripotent-stem-cell-derived endothelial and smooth-muscle cells assembled into perfused tissue-engineered blood vessels, enabling investigators to measure the arterial dysfunction that is most relevant to heart attack and stroke. Base-editing studies also use deep DNA sequencing to quantify intended correction, unintended nearby “bystander” changes, and insertion/deletion errors. Base editing in engineered HGPS blood vessels In vivo base editing rescues HGPS in mice

Biomarker development is becoming central to smaller, faster rare-disease trials. An ultrasensitive blood immunoassay can measure circulating progerin; untreated participants with HGPS had mean plasma levels about 95 times those in non-HGPS participants, and lonafarnib-associated reductions in progerin correlated with better survival in longitudinal modeling. Such biomarkers may help determine whether a therapy is reaching its biological target before definitive cardiovascular outcomes are available. Plasma progerin biomarker study

Leading Institutions and Funding

The base-editing program has involved the Broad Institute of MIT and Harvard, Harvard University, the National Human Genome Research Institute at NIH, Vanderbilt University Medical Center, the University of Maryland, Boston Children’s Hospital, Brown University, and the Progeria Research Foundation (PRF). The 2021 editing work was supported by multiple NIH components, including NHGRI, the NIH Common Fund, NHLBI, NIAID, NIBIB, NIGMS, and NCATS, as well as PRF support. NIH summary of base editing study In vivo base editing rescues HGPS in mice

PRF remains the principal patient-foundation organizer, supporting cell and tissue resources, clinical trial infrastructure, and grants. Its audited 2024 financial statements reported $250,000 in donor-restricted assets for gene base editing and approximately $41.5 million in investments at year-end, illustrating substantial philanthropic capacity for a disease affecting very few children worldwide. PRG Science & Technology is sponsoring the progerinin trial, while Boston Children’s Hospital leads the everolimus-lonafarnib study. PRF 2024 financial statements NCT06775041: Progerinin plus lonafarnib NCT02579044: Everolimus plus lonafarnib

Strengths, Limitations, and Challenges

HGPS has an exceptional advantage for precision medicine: most classic cases result from the same single-nucleotide LMNA variant. This makes one-time correction conceptually feasible, and base editing has improved survival and vascular disease in mice rather than only correcting cells in a dish. The availability of a measurable progerin biomarker, established international care networks, and an approved standard therapy also strengthen clinical development. NIH summary of base editing study Plasma progerin biomarker study

The central obstacle is safe, body-wide delivery. The 2021 mouse strategy required two AAV vectors because the base editor is too large for one vector, and different organs received different levels of editing. Researchers must show durable correction in human coronary and cerebral arteries, characterize unintended edits, manage immune responses to the delivery vehicle and editor, and determine whether treatment can repair established vascular damage or must be given very early. RNA therapies avoid permanent editing but may require repeated dosing; small molecules may be easier to administer but do not remove the mutant DNA sequence. The tiny patient population also makes adequately powered trials, long-term safety follow-up, manufacturing, and equitable global access difficult. In vivo base editing rescues HGPS in mice Systematic ASO screening for HGPS

Outlook and Future Directions

As of August 8, 2026, HGPS is not curable, but it is one of the clearest candidates for a future single-treatment genetic cure because its dominant cause is usually one correctable DNA letter. The milestones to watch are publication of Phase 2a progerinin results, clinical results from everolimus-lonafarnib combination treatment, validation of plasma progerin as a surrogate marker, and completion of manufacturing, regulatory, and safety packages needed to bring base editing into a first-in-human HGPS study. Near-term progress is more likely to be improved combination disease-modifying therapy; a true cure will require convincing evidence that systemic mutation correction is safe and can durably protect the cardiovascular system in children. NCT06775041: Progerinin plus lonafarnib GeneReviews: HGPS PRF gene-editing program update

References

• GeneReviews: HGPS — Gordon, Brown, and Collins / NCBI Bookshelf, 2025.
• FDA Zokinvy approval letter — U.S. Food and Drug Administration, 2020.
• FDA Zokinvy prescribing information — U.S. Food and Drug Administration, 2024.
• In vivo base editing rescues HGPS in mice — Koblan et al., Nature, 2021.
• NIH summary of base editing study — National Institutes of Health, 2021.
• Systematic ASO screening for HGPS — Puttaraju et al., Nature Medicine, 2021.
• Selective siRNAs for HGPS — Dobrzyńska et al., Molecular Therapy: Nucleic Acids, 2025.
• Progerinin in HGPS cells — Kang et al., Communications Biology, 2021.
• Progerinin improves cardiac abnormalities in mice — Kang et al., Cells, 2023.
• Ghrelin in HGPS fibroblasts — Ferreira-Marques et al., Aging Cell, 2023.
• NCT06775041: Progerinin plus lonafarnib — ClinicalTrials.gov, 2026.
• NCT02579044: Everolimus plus lonafarnib — ClinicalTrials.gov, 2026.
• Lonafarnib and everolimus in engineered vessels — Abutaleb et al., Aging Cell, 2023.
• Base editing in engineered HGPS blood vessels — Abutaleb et al., APL Bioengineering, 2025.
• Plasma progerin biomarker study — Gordon et al., Circulation, 2023.
• In vivo base editing rescues HGPS in mice — Koblan et al., Nature, 2021.
• PRF 2024 financial statements — The Progeria Research Foundation, 2025.
• PRF gene-editing program update — The Progeria Research Foundation, 2025.